UBS AM
IRMD icon

UBS AM’s iRadimed IRMD Stock Holding History

UBS AM’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
14,736
-389
-3% -$35.4K ﹤0.01% 2211
2026
Q1 		$1.46M Buy
15,125
+250
+2% +$25K ﹤0.01% 2184
2025
Q4 		$1.45M Buy
14,875
+2,595
+21% +$223K ﹤0.01% 2009
2025
Q3 		$874K Sell
12,280
-13,796
-53% -$919K ﹤0.01% 2049
2025
Q2 		$1.56M Buy
26,076
+7,108
+37% +$390K ﹤0.01% 2249
2025
Q1 		$995K Buy
18,968
+609
+3% +$34.2K ﹤0.01% 2313
2024
Q4 		$1.01M Buy
18,359
+8,774
+92% +$462K ﹤0.01% 2360
2024
Q3 		$482K Sell
9,585
-2,446
-20% -$113K ﹤0.01% 2654
2024
Q2 		$529K Buy
+12,031
New +$512K ﹤0.01% 2615

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's IRMD Position: Q2 2026 in Review

UBS AM reduced its iRadimed (IRMD) stake by 2.6% in Q2 2026, selling an estimated $35.4K and leaving 14,736 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

UBS AM first reported a position in IRMD in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.56M in Q2 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • UBS AM held 14,736 shares of iRadimed worth $1.41M as of Q2 2026.
  • UBS AM sold 389 iRadimed shares in Q2 2026, an estimated $35.4K.
  • iRadimed made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2211 holding.
  • UBS AM first reported a position in iRadimed in Q2 2024 and has held it in 9 quarters since.
  • UBS AM's iRadimed position peaked at $1.56M in Q2 2025.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.